U.S. Markets closed

TrovaGene, Inc. (TROVU)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.58+0.06 (+3.95%)
At close: 4:00PM EDT
  • NEWBIE, bash-TURDING! REVENUE, just rolling in from last year still, per conference call. And we know once you are on the roll what happens. BAM! POW! KA-BOOOOMMMM!
  • Trov is fixing to Skyrocket!
  • I wonder when trov will get there delisting notification. the stock will drop to 50 or 60 cents. they will dilute heavy at 50 cents imo up to 100 million shares outstanding. then imo the stock will fall to about 30 cents and they will do a 1 for 10 reverse. let's see what happens
  • I heard mgm is pan handling in the streets of Florida. so sad. his sune idra and trov all turned out to be turds.
  • bash-TURDING NEWBI, and older jkng him off. LMFAO!
  • Revs are decreasing at Trov on a quarter x quarter basis while BIOC's are increasing at an even faster pace. Seems BIOC is taking sample sales away from TROV.
  • Letitgrow, where the heck are those pompons girl ??
  • NEVER BEEN BETTER! MONEY WILL BE ROLLING IN, PERIOD! Deals news and BAM! POW! KA-BOOOOMMMM!
  • I am very disappointed in management. They have a great platform they decided to put on the back burner in favor of a new venture? They have lost focus and I don't understand exactly why. Something just doesnt smell right. Can somebody objectively explain this to me who is not a perpetual long or short but considers themselves an investor.
  • 74 cents.. nice...
  • 95k revenue, you got to be kidding me.
  • "We are excited about the advancement of our business in precision medicine and the development of precision cancer therapeutics for improved cancer care. This includes the licensing and progress in our clinical development plans for PCM-075, our investigational, oral and highly-selective polo-like kinase 1 (PLK1) inhibitor for the treatment of acute myeloid leukemia (AML)," said Bill Welch, Chief Executive Officer of Trovagene. "I am also pleased to announce that we have entered into two separate agreements with large international pharmaceutical companies to provide our CLIA/CAP-accredited tests and laboratory services. Both companies plan to use our Trovera(R) liquid biopsy tests to evaluate patients' response to treatment in their clinical trials."
  • It was a strange CC, in that neither management nor the analysts addressed the elephant in the room: where will TROV get more money? Cash on hand is $29.8 million, projected quarterly cash burn rate is $4-5M. That gives them 5 or 6 quarters before they'll have to turn the lights out, not even enough time to get PCM-075 through phase 1/2, much less phase 3.
  • mgMORON = helmut
  • I just found out I could mute Helmut, so I don't have to see his stupid comments and 3rd world grammar.
    Imagegifsme
  • this company is headed to the #$%$!!! what a joke!
  • I own a shtt. load of TROV, and a lot way down here. Made 12999, last year without effort. And wl do 25,000 without effort this year. Last year not long term but already have 12,000 shhares long term... NICE.. TROV, has never ever been better. They have signed of big international companies. Collection will be huge and use TROV, stuff universally too. We are getting to be a conglomerate here. WHEEE! LIKE IT! MY HUMBLE OPINION! More you have (opinions), the less they are worth. BEEN SAYING all they did that they would.. Just need some bucks roilling in. REVENUE! Just like Ammazon. After 7 yrars they final made a few bucks, now on the roll, maybe. HMMM!
  • I hope the stock goes to whatever price that will get the negativity gone. I bought and sold stocks and nor ONCE ever went back and posted negative #$%$ after I sold it. Spend your time with your girl or something for crying out loud. Going to message boards of stocks you do not own is almost like stocking. GET A LIFE!!
  • These NON stock holder bash-TURDS are jkng each other furiously. I have a buy in. MORE FOR LESS for at least one week. They csn play this with 7 cents diff a dya nad make a shtt. load of money.. WHO? WS! MF. GS, and MS, 16,000 traders is who.
  • I'm a shareholder and very concerned about a misrepresentation in the 10Q that got released. In note 9 it talks about the litigation with the former CEO and CFO. It talks about the "therapeutics" that this company has that were required to be turned over to TROV. I know about this company and what they had as assets. There were no therapeutic assets. That is complete male bovine excrement. I question the Board here for going down such a misguided path. I think the other shareholders of this start up company should be suing TROV and the Board personally for tortious interference with business relations.